免疫抑制剂与COVID-19的悖论
本文基于大型登记研究分析,探讨免疫抑制治疗(IST)在COVID-19中的矛盾作用。既往暴露于糖皮质激素的患者COVID-19结局更差,但IST是否既促进又防护重症COVID-19尚需明确。
要点
- 既往糖皮质激素暴露与COVID-19不良结局相关
- 免疫抑制患者被视为感染易感人群
- IST在COVID-19中可能同时具有促进和防护作用
核心结论
- 大型登记研究分析显示,既往暴露于糖皮质激素的患者COVID-19结局更差。
- 免疫抑制治疗在COVID-19中可能存在促进与防护并存的悖论。
研究设计与样本
- 基于大型登记研究的分析(原文未报告具体样本量)。
主要发现
- 既往暴露于糖皮质激素的患者COVID-19结局更差。
- 接受免疫抑制治疗的患者常被视为免疫功能受损,感染易感性增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lessons learned from a large registry analysis show worse COVID-19 outcomes for patients previously exposed to glucocorticoids https://bit.ly/306rNrk For millions of people, taking immunosuppressive medication to control or prevent disease is a daily reality [1]. Rheumatological disease, inflammatory lung disease, organ transplantation and graft-versus-host disease are but a few of the immune dysregulation syndromes that may require short- or long-term immunosuppressive therapy (IST). Patients taking ISTs are frequently regarded as immunocompromised, sharing risks of increased infection susceptibility with cancer patients receiving chemotherapy, those with profound neutropenia from haematological malignancies, and individuals living with HIV. In the context of the immune-mediated respiratory failure associated with coronavirus disease 2019 (COVID-19), an apparent paradox arises: can ISTs both promote and protect against severe COVID-19?
引用
- Cheng GS, Evans SE. The paradox of immunosuppressants and COVID-19. Eur Respir J. 2022. PMID: 34795039. doi:10.1183/13993003.02828-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。